

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

<https://marketpublishers.com/r/O8675CB7400EN.html>

Date: June 2017

Pages: 26

Price: US\$ 2,000.00 (Single User License)

ID: O8675CB7400EN

Abstracts

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline landscape.

Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-esophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).

The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in
Therapeutics Development

ChironWells GmbH

RaQualia Pharma Inc

Vitality Biopharma Inc

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Drug Profiles

ORP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORP-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders - Drug
Profile

Product Description

Mechanism Of Action

R&D Progress

VB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by ChironWells GmbH, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by RaQualia Pharma Inc, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Vitality Biopharma Inc, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

ChironWells GmbH

RaQualia Pharma Inc

Vitality Biopharma Inc

I would like to order

Product name: Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/O8675CB7400EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O8675CB7400EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970